Thursday, December 15, 2005

FDA Approves Avelox for Abdominal Infections

....The indication covers abscesses caused by E. coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron, or Peptostreptococcus species, the company said. The drug is available in both tablet and IV formulations....

...The overall success rate was 79.8% for the single-dose Avelox group versus 78.1% for the piperacilin-tazobactam group, Schering-Plough said...

FDA Approves Avelox for Abdominal Infections..Read more

No comments: